Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 16, 2009

View Archived Issues

Novel Hsp90 inhibitors under development at Merck KGaA for the treatment of cancer

Merck & Co. imparts novel HDAC inhibitors for treating cancer

Torrent claims novel Hsp70 inducers with potential for treating stroke

Novel deuterated oseltamivir analogues developed at Protia for influenza

Recent Dainippon Sumitomo patent reports new renin inhibitors with antihypertensive properties

Protia imparts novel deuterated tenofovir analogues with anti-HIV properties

NeoPharm submits application to FDA for phase II study of LE-DT in prostate cancer

Astex and Cancer Research U.K. sign CTA for AT-9283 in childhood cancer

Dainippon Sumitomo recaps Q3 developments

Novogen plans to focus activities on its oncology program

No serious adverse events seen with OBP-601 in phase I study

NeuroSearch discontinues ABT-894 program in diabetic neuropathic pain

Oasmia's phase III Paclical study generates physician interest in Europe

Octapharma commences phase II study of Octagam in Alzheimer's disease

Oral laquinimod granted FDA fast track designation for multiple sclerosis

Conditionally replicative adenovirus shows activity in phase I ovarian cancer trial

Roche signs nonexclusive license agreement with MDRNA for RNAi-based therapeutics

HIV-1 subtype A/E vaccine is safe but not highly immunogenic in healthy Thai subjects

Telik implements reorganization to focus on Telintra and leading preclinical candidates

CD4 T cells modified ex vivo by lentiviral vector traffic to lymphoid tissues in HIV patients

Antisense presents update on development

IDMC for phase III trial of motesanib recommends resumption of enrollment

Doctors can now predict Pegasys treatment success in hepatitis B patients

France approves named patient supply for Ark's Cerepro

Teijin and Takeda receive FDA approval for febuxostat for hyperuricemia in gout

ViroPharma discontinues maribavir phase III liver transplant study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...